Clinical Relevance of the HD sEMG Signals in the Post-stroke Rehabilitation

Alain Kaelin40 enrolled

Overview

The goal of this clinical trial is to learn about the WPM-SEMG-V2 device (Wireless Portable and Multi-Channel, WPM) designated to acquire high-density (HD) surface electromyography (sEMG) signals in healthy volunteers and post-stroke patients. The main objectives are: 1) to technically and clinically validate the WPM-SEMG-V2 device in healthy volunteers; 2) to demonstrate the clinical relevance of the HD sEMG signals to support the process of rehabilitation of post-stroke patients. Participants will be asked to perform simple exercises using the muscles of the hand or the leg in static or dynamic contractions while wearing the WPM-SEMG-V2 device.

The participant will be instructed how to execute static or the dynamic exercises while wearing the WPM-SEMG-V2 device. The WPM-SEMG-V2 device will be initially tested in a small number of healthy volunteers to evaluate the technical and clinical performance of the device in different settings (i.e., static and dynamic muscle contractions). Preliminary information gathered in the first part of the investigation may eventually guide further device modifications. The second part will capture preliminary clinical performance of the device in post-stroke patients. The main aim is to study the behaviour of the neuromuscular system in voluntary muscle activations and demonstrate the clinical relevance of the HD sEMG signals to support the process of rehabilitation of post-stroke subjects.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

OTHER

Masking

NONE

Enrollment

Conditions

Stroke

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: Healthy volunteers * Written Informed Consent * Female or male * 18 years or older * Ability to understand the investigation * Willingness to complete all the investigation assessments * Ability to perform the procedures of the investigation * Ability to perform maximal voluntary muscle extension of the target muscle and limb Additional inclusion criteria only for the recreationally active or athletic, healthy volunteers : * Subjects who participated in at least 150 min of moderate activity per week over the last six months. * between 18 and 20 years (preferably) Post-stroke patients * Written informed consent * Female or male * 18 years or older * Have a first-time stroke * Ability to perform maximal voluntary muscle extension of the target muscle and limb * Preserved cognitive capacity to perform the task * Ability to understand the investigation * Willingness to complete all the investigation assessments * Ability to perform the procedures of the investigation Exclusion Criteria: Healthy volunteers * Any significant acute disease state * Skin disorders/allergies at the site of contact with the investigational device * History of skin disease * Known hypersensitivity or allergy to component of the investigational product (e.g. metal alloys) or other materials used (e.g., abrasive gel, foam with polystyrene markers) * Chronic use of medications or treatment Post-stroke patients * History of spinal cord injury or traumatic brain damage * Serious medical illness that precludes performing the task * Severe locomotion disorder due to other causes * Severe neurological disease other than stroke * Any significant acute disease state * Skin disorders/allergies at the site of contact with the investigational device * History of skin disease * Known hypersensitivity or allergy to component of the investigational product (e.g. metal alloys) or other materials used (e.g., abrasive gel, foam with polystyrene markers)

Outcomes

Primary Outcomes

Technical performance of the device (0 to 2)

Assessed during signal acquisitions in static and/or dynamic contractions in healthy volunteers by checking the following parameters: 1. Interaction (0 or 1): when the WPM-SEMG-V2 is connected to the component for trapezoidal force measurement, both the sEMG signals and force data are recorded by the device on the device's SD card. 2. Availability (0 or 1): all data recordings are stored separately in the SD card. 3. Integrity of the final data (0 or 1): the recorded signals have the same duration of the recordings after post-processing of the data timestamp. The technical performance of the device is defined as Interaction\*(availability+integrity) in static contractions. The technical performance of the device is the sum of the scores for availability and integrity in dynamic contractions.

Time frame: 1 day

Quality of the WPM-SEMG-V2 device in the acquisition of HD sEMG signals (0 to 2)

Assessed during signal acquisitions in static and/or dynamic contractions, both in healthy volunteers and post-stroke patients by measuring the following parameters: 1. Signal amplitude (0 or 1): the peak-to-peak sEMG signal amplitude is within the anatomical range of few-tens of µV to 2 mV. 2. Signal spectrum (0 or 1): the sEMG signal spectrum is within the anatomical range (sEMG power is mostly accounted for by the frequency components \< 350 Hz). Quality of the WPM-SEMG-V2 device in the acquisition of HD sEMG signals is the sum of the scores given to signal amplitude and signal spectrum.

Time frame: 30 days

Correlation between the properties of populations of Motor Unit (MU) with the type of the stroke.

Assessed during signal acquisitions in static contractions in post-stroke patients. The following properties will be extracted from the MUs populations: discharge rate (pulses/seconds), recruitment threshold (percentage of the maximum voluntary force contraction), motor unit conduction velocity (meter/seconds), Muscle Fiber Conduction Velocity (meter/seconds. Type of stroke: acute or subacute.

Time frame: 30 days

Correlation between the properties of populations of Motor Unit (MU) with the severity of the stroke.

Time frame: 30 days

Correlation between the properties of populations of Motor Unit (MU) with the location of the stroke.

Time frame: 30 days

Percentage of tracked MU

Defined as the number of tracked MU / number of detected MUs in the baseline session, among the baseline, medium term, and long term sessions. Assessed during signal acquisitions in static contractions, both in healthy volunteers and post-stroke patients

Time frame: 30 days

Secondary Outcomes

Incidence of serious and non-serious adverse event, adverse device effect, device deficiency and malfunction

As assessed by reported adverse event.

Time frame: 30 days

Clinical Relevance of the HD sEMG Signals in the Post-stroke Rehabilitation

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts